NCT06535269

Brief Summary

To demonstrate that postoperative pain secondary to Milligan and Morgan hemorrhoidectomy with Caiman® (AESCULAP®) and subsequent oral conventional analgesia is at least not greater than that generated after hemorrhoidectomy with monopolar diathermy and intravenous analgesia with care home at discharge.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
27

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Nov 2022

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 2, 2022

Completed
1.7 years until next milestone

First Submitted

Initial submission to the registry

July 11, 2024

Completed
22 days until next milestone

First Posted

Study publicly available on registry

August 2, 2024

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2025

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2025

Completed
Last Updated

August 2, 2024

Status Verified

August 1, 2024

Enrollment Period

2.2 years

First QC Date

July 11, 2024

Last Update Submit

August 1, 2024

Conditions

Outcome Measures

Primary Outcomes (1)

  • Visual analogue scale (VAS)

    Postoperative pain: value 0 (no pain) - 10 (maximum pain)

    6 hours of post-operative period (before hospital discharge performed); within 2 days with telephone control; at 7 days control at external consultations; at 30 days control at external consultations

Secondary Outcomes (5)

  • Wound healing time

    7 days postoperative control at external consultations; 30 days postoperative control at external consultations

  • Post-surgery satisfaction survey

    30 days postoperative control at external consultations

  • Wexner scale

    in pre-operative visit, on the 7th and 30th postoperative clinical control

  • Number of emergency consultations

    in 30 days post-surgery

  • Collection of adverse effects from patients

    in 30 days post-surgery

Study Arms (2)

Control

ACTIVE COMPARATOR

Conventional hemorrhoidectomy with monopolar diathermy + intravenous analgesia with elastomeric pump + discharge with home hospitalization.

Procedure: Monopolar Hemorroidecotmy

Experimental

EXPERIMENTAL

conventional haemorrhoidectomy with Caiman® bipolar energy (AESCULAP®) + oral conventional analgesia + conventional home discharge.

Procedure: Caiman Hemorroidectomy

Interventions

Hemorrhoidectomy with monopolar diathermy

Control

Hemorrhoidectomy with Caiman® bipolar energy

Experimental

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • All patients with 2 or 3 bundles of grade III-IV hemorrhoids (Goligher classification) clinically symptomatic and subject to outpatient hemorrhoidectomy
  • Voluntary participation.
  • ASA I-II-III.

You may not qualify if:

  • ASA IV.
  • Allergic to Paracetamol, derivatives of morphine.
  • Allergic to NSAIDs.
  • Synchronous colorectal neoplasia.
  • Coagulation disorders.
  • Thrombosed hemorrhoid.
  • Inflammatory bowel disease.
  • Liver cirrhosis and/or portal hypertension.
  • Pregnant women.
  • Difficulty following up by phone and/or in person.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Laura Mora López

Sabadell, Barcelona, 08208, Spain

RECRUITING

Related Publications (8)

  • Perera N, Liolitsa D, Iype S, Croxford A, Yassin M, Lang P, Ukaegbu O, van Issum C. Phlebotonics for haemorrhoids. Cochrane Database Syst Rev. 2012 Aug 15;2012(8):CD004322. doi: 10.1002/14651858.CD004322.pub3.

    PMID: 22895941BACKGROUND
  • Alonso-Coello P, Guyatt G, Heels-Ansdell D, Johanson JF, Lopez-Yarto M, Mills E, Zhou Q. Laxatives for the treatment of hemorrhoids. Cochrane Database Syst Rev. 2005 Oct 19;2005(4):CD004649. doi: 10.1002/14651858.CD004649.pub2.

    PMID: 16235372BACKGROUND
  • Shanmugam V, Thaha MA, Rabindranath KS, Campbell KL, Steele RJ, Loudon MA. Rubber band ligation versus excisional haemorrhoidectomy for haemorrhoids. Cochrane Database Syst Rev. 2005 Jul 20;2005(3):CD005034. doi: 10.1002/14651858.CD005034.pub2.

    PMID: 16034963BACKGROUND
  • Medina-Gallardo A, Curbelo-Pena Y, De Castro X, Roura-Poch P, Roca-Closa J, De Caralt-Mestres E. Is the severe pain after Milligan-Morgan hemorrhoidectomy still currently remaining a major postoperative problem despite being one of the oldest surgical techniques described? A case series of 117 consecutive patients. Int J Surg Case Rep. 2017;30:73-75. doi: 10.1016/j.ijscr.2016.11.018. Epub 2016 Nov 15.

    PMID: 27960130BACKGROUND
  • Nienhuijs S, de Hingh I. Conventional versus LigaSure hemorrhoidectomy for patients with symptomatic Hemorrhoids. Cochrane Database Syst Rev. 2009 Jan 21;2009(1):CD006761. doi: 10.1002/14651858.CD006761.pub2.

    PMID: 19160300BACKGROUND
  • Gentile M, De Rosa M, Carbone G, Pilone V, Mosella F, Forestieri P. LigaSure Haemorrhoidectomy versus Conventional Diathermy for IV-Degree Haemorrhoids: Is It the Treatment of Choice? A Randomized, Clinical Trial. ISRN Gastroenterol. 2011;2011:467258. doi: 10.5402/2011/467258. Epub 2010 Nov 21.

    PMID: 21991510BACKGROUND
  • World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013 Nov 27;310(20):2191-4. doi: 10.1001/jama.2013.281053. No abstract available.

    PMID: 24141714BACKGROUND
  • Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gotzsche PC, Krle A-Jeric K, Hrobjartsson A, Mann H, Dickersin K, Berlin JA, Dore CJ, Parulekar WR, Summerskill WS, Groves T, Schulz KF, Sox HC, Rockhold FW, Rennie D, Moher D. SPIRIT 2013 Statement: defining standard protocol items for clinical trials. Rev Panam Salud Publica. 2015 Dec;38(6):506-14.

    PMID: 27440100BACKGROUND

Study Officials

  • Laura Mora

    Parc Tauli University Hospital

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: Non-inferiority, prospective, randomized, single-center, parallel-group clinical trial.
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
PhD, MD, Colorrectal Surgeon, Associate Professor

Study Record Dates

First Submitted

July 11, 2024

First Posted

August 2, 2024

Study Start

November 2, 2022

Primary Completion

January 1, 2025

Study Completion

July 1, 2025

Last Updated

August 2, 2024

Record last verified: 2024-08

Data Sharing

IPD Sharing
Will not share

Locations